Key Takeaways
- CMS's 2.5% efficiency adjustment on roughly 7,700 non-time-based codes effectively erases the headline 3.3% conversion factor increase, leaving facility-based hematology/oncology practices absorbing up to 11% net payment cuts in 2026.
- The dual conversion factor structure ($33.57 for qualifying APM participants vs. $33.40 for non-QPs) creates a clear financial incentive to migrate into advanced APMs, but practices that haven't begun evaluation are realistically targeting 2027 entry at the earliest.
- CMS added 560 procedures to the ASC Covered Procedures List for 2026 and cut facility-based indirect PE to 50% of non-facility rates, making ASC migration the most immediate site-of-care arbitrage available to surgical and ophthalmology specialties.
- Co-management arrangements and PSAs tied to the new TEAM episode-based payment model provide rate-neutral income that doesn't depend on fee schedule mechanics, serving as a margin bridge during longer structural transitions.
- Ancillary revenue buildout (infusion centers, pathology, imaging) is the only offset that fully bypasses the physician fee schedule, but capital timelines mean practices making those decisions now won't see revenue until 2027-2028.
The 2026 Medicare Physician Fee Schedule created an accounting illusion. CMS raised the conversion factor to $33.40 for non-qualifying APM participants (up from $32.35 in 2025), generating trade press coverage about the first meaningful physician payment increase in years. What that coverage buried was the simultaneous imposition of a 2.5% efficiency adjustment across roughly 7,700 non-time-based procedural and diagnostic codes, confirmed in the CMS final rule fact sheet. For procedural specialties, the conversion factor gain and the RVU reduction largely cancel out, producing approximately a 1% net decrease. For hematology and oncology practices operating in facility settings, the damage is far greater: Oncology Practice Solutions estimates a reimbursement decrease of approximately 11% for facility-based physicians, while the AMA projects that 37% of oncologists will face reductions in the 10-20% range.
Revenue cycle teams cannot absorb that through denial management. The practices that maintain financial viability through 2027 are the ones executing structural changes now: APM migration, site-of-care arbitrage, deliberate service line culling, co-management agreements, and ancillary revenue buildout. Each of these moves has a lead time measured in months, not weeks. Practices still in the analysis phase are running out of runway.
Why Coding Optimization and Denial Appeals Won't Be Enough This Cycle
Denial management and coding capture improvements are genuine revenue cycle levers, but they carry a hard ceiling: accurate billing of correctly documented services at current fee schedule rates. When the fee schedule itself is the problem, optimizing the billing process is a marginal exercise.
The efficiency adjustment specifically targets the codes that make procedural specialties financially viable. CMS's rationale, that technological improvements and learning curves have shortened real-world procedure time, transfers that productivity gain to the federal government rather than to the practice that invested in the equipment. For oncology practices billing IGRT and radiation delivery codes (revised under the new CPT structure for 2026), for ophthalmology practices billing cataract extraction, and for surgical practices across multiple specialties, the affected codes represent the revenue core. Buckhead FMV's analysis confirms that surgeons and proceduralists face work RVU decreases across affected codes, with certain service lines now generating negative contribution margin at Medicare rates. Tightening documentation and reducing write-offs can recover 1-3% of revenue in favorable circumstances. That doesn't neutralize a double-digit facility-based payment cut.
The APM Migration Window: Which Specialty Practices Qualify and Which Are Already Too Late
The 2026 fee schedule formalized a two-tier payment system. Qualifying APM Participants receive a conversion factor of $33.57 versus $33.40 for non-participants. The per-RVU premium is modest in isolation but compounds meaningfully at volume. More consequentially, QPs are exempt from MIPS reporting burdens and eligible for model-specific performance payments, reducing both administrative cost and compliance risk.
CMS expanded QP thresholds for 2026 to include both entity-level and individual-level qualification in advanced APMs, broadening the eligible pool beyond what prior-year rules permitted. For oncology practices, the Transforming Episodic Accountability Model (TEAM), effective January 1, 2026, creates episode-based payment arrangements covering cancer surgery episodes and can serve as a co-management infrastructure. ASCO's policy analysis identifies this structural bifurcation as one of the most significant reimbursement methodology changes finalized for the cycle.
The migration window is narrowing for 2027 entry. APM qualification requires participation commitments, operational restructuring, and alignment with qualified entities that take 12-18 months to execute. Practices that haven't begun evaluation face a 2028 implementation floor at best, meaning two more years of non-QP conversion factors on top of the efficiency adjustment. The practices positioned to benefit from QP status in 2026 started this process in 2024.
Site-of-Care Arbitrage: Moving Volume to ASCs Before the Efficiency Adjustment Compounds
CMS's own policy architecture in the 2026 rule sends a clear directional signal: procedures performed in facility settings attract lower physician payment because CMS assumes the facility absorbs overhead costs. The new indirect practice expense methodology reduces facility-based indirect PE to 50% of the non-facility rate. For hospital-based proceduralists, that PE compression compounds directly on top of the efficiency adjustment.
The countermove is ASC migration, and the 2026 rule made it structurally more accessible. CMS added 560 newly eligible procedures to the ASC Covered Procedures List for 2026, including 271 procedures removed from the Inpatient Only list. According to Ophthalmology Management's ASC reimbursement analysis, ASCs perform ophthalmic procedures at 40-60% lower costs than hospital outpatient departments, and CMS applied a 2.4% facility payment increase to ASC services for 2026. The finalized ASC facility rate for cataract extraction (CPT 66982/66984) is $1,255.73, a 3.4% increase, meaningful for ophthalmology practices where cataract volume drives facility economics.
For surgical practices more broadly, the calculation is direct: identical procedures now yield higher effective margins in ASC settings, and the gap widens each time the efficiency adjustment renews. The strategic constraint is timeline. ASC development and partnership structuring requires capital, state licensure, and credentialing processes that typically run 18-24 months. Practices accelerating this in early 2026 are building the cost structure that will sustain them through the next fee schedule cycle.
Service Line Culling: The Hard Math Behind Dropping Low-RVU Procedures
The efficiency adjustment accelerates a rationalization process that financially disciplined practices have been running for years. When a procedure's reimbursement falls below the combined cost of physician time, support staff, overhead allocation, and supply, continuing to offer it at Medicare rates is a subsidy to the program, not a margin contributor.
The 2026 adjustment hits injectable and infusion-adjacent procedures particularly hard where drug acquisition cost exceeds the bundled administration payment. MGMA's 2026 reimbursement survey documents practices already eliminating specific procedure offerings and shifting toward cash-pay or hybrid models where clinically appropriate. Anesthesia reimbursement faces similar pressure.
Culling a service line is a governance decision requiring both financial modeling and patient access planning. The practices executing it deliberately are running procedure-level contribution margin analysis, identifying the bottom quartile of margin-per-RVU performers, and making explicit discontinuation decisions. The practices that don't run this analysis formally will implement it implicitly through physician attrition and operational drift, which is a more expensive way to arrive at the same outcome.
Co-Management and Professional Services Agreements as a Margin Bridge
Clinical co-management arrangements (CCMAs) between specialty practices and health systems generate income that doesn't depend on fee schedule mechanics. The standard structure combines a fixed base payment for defined administrative and quality responsibilities with performance-based incentive payments tied to measurable outcomes. For oncology, cardiology, and orthopedic practices, these arrangements compensate physician leadership for driving cost reduction and quality improvement in service lines where they hold clinical authority.
The 2026 TEAM model creates a co-management infrastructure opportunity specifically because the episode-based payment structure requires coordination across care settings and physician groups. PYA's analysis of CCMAs positions these arrangements as providing revenue independent of fee schedule rates, making them one of the few genuinely rate-neutral income streams available to independent specialty practices. PSAs offer a simpler variation for practices seeking compensation for administrative and coverage services without the full performance-at-risk structure of a CCMA.
Neither arrangement replaces the need for structural transformation, but both generate margin while practices execute longer-lead transitions like APM migration and ASC development.
Ancillary Revenue Buildout: Infusion, Pathology, and Imaging as the Structural Offset
The most durable financial offset to fee schedule compression is ancillary revenue that doesn't appear on the physician fee schedule. Infusion services, in-house pathology, and diagnostic imaging generate revenue under HOPPS, the clinical laboratory fee schedule, and technical component payments. For qualifying practices, the 340B drug pricing program creates a drug acquisition discount that translates into margin on chemotherapy and biologic administration, with 340B Health documenting oncology as the most financially affected therapeutic area under the program.
ImagineSoftware's infusion center analysis identifies chair utilization as the defining operational metric: an infusion center running at 80%+ utilization generates margin that structurally absorbs physician fee schedule losses at the practice level. Drug administration services under the 2026 HOPPS receive 40% of the outpatient department rate, a CMS policy designed to reduce site-of-care financial incentives, but practices with existing infusion infrastructure capture that margin within a non-facility cost structure.
The build-out timeline is the binding constraint. Infusion infrastructure requires capital, pharmacy arrangements, state licensure, and nursing staff. Practices treating ancillary buildout as a 2026 decision will see revenue impact in 2027-2028 at the earliest. The practices using infusion and imaging as meaningful fee-schedule offsets today built that capacity in 2023-2024.
The efficiency adjustment has no defined end point. CMS applies a five-year Medicare Economic Index productivity lookback to derive each cycle's adjustment, creating a structural ratchet where each wave of technological adoption becomes the new baseline for the next reduction. Specialty practices that frame 2026 as an anomaly to absorb and wait out will find 2027 structurally identical, only further along the compression curve. The five pivots outlined here have different time horizons and capital requirements, but they share a common premise: the fee schedule is not going to rescue procedural medicine's economics. The practices that internalized that premise in 2024 are executing now. Everyone else is deciding how many cycles they can afford to lose.
Frequently Asked Questions
What exactly is the 2026 Medicare efficiency adjustment and why does it hit procedural specialties hardest?
CMS applied a 2.5% reduction to physician work RVUs and intraservice time for approximately 7,700 non-time-based procedural and diagnostic codes, citing research that technology adoption has reduced real-world procedure time. Time-based codes including E/M visits, care management, and behavioral health services are exempt from the adjustment. Because procedural specialties like oncology, ophthalmology, and surgery derive the majority of their RVU volume from non-time-based codes, the AMA projects that 37% of oncologists will see payment reductions in the 10-20% range.
Which oncology APMs are viable migration pathways for practices that haven't already entered one?
The Transforming Episodic Accountability Model (TEAM), effective January 1, 2026, creates episode-based payment arrangements applicable to cancer surgery episodes and can function as a co-management platform across care settings. CMS also expanded QP qualification for 2026 to include both entity-level and individual-level thresholds in advanced APMs, broadening eligibility beyond prior-year rules. The practical implementation timeline for APM entry remains 12-18 months, placing 2027-2028 as the realistic target for practices beginning evaluation now.
How does ASC site-of-care migration improve physician economics under the 2026 rule?
The 2026 MPFS reduced indirect practice expense RVUs for facility-based services to 50% of the non-facility rate, directly compressing physician payment for procedures performed in hospital outpatient settings. Simultaneously, CMS raised ASC facility payments by 2.4% and added 560 procedures to the ASC Covered Procedures List, and ASCs operate at 40-60% lower cost than hospital outpatient departments. The combined effect is that the same procedure generates a materially higher effective margin in an ASC setting, with the gap widening as the efficiency adjustment renews in subsequent cycles.
What Stark Law considerations govern clinical co-management arrangements under the TEAM model?
CCMAs must meet the personal services exception under Stark Law, requiring that physician compensation be consistent with fair market value and structured so it does not take into account the volume or value of referrals. PYA recommends independent FMV assessments covering both the base administrative compensation and any performance-based incentive structure, given that CMS scrutiny of CCMA arrangements has increased alongside value-based care expansion. The TEAM model's episode-based structure introduces additional documentation requirements for demonstrating that management services rendered match the compensation paid.
Is the efficiency adjustment a one-time policy or will it recur in future fee schedule cycles?
CMS provided no sunset provision or defined end point for the efficiency adjustment mechanism in the 2026 final rule. The policy uses a five-year Medicare Economic Index productivity lookback to calculate each cycle's adjustment, creating a ratchet structure where efficiency gains from technology adoption become the new baseline for the next reduction. The AMA and specialty societies including ASTRO and COA have formally objected, but absent Congressional action specifically targeting the adjustment methodology, the mechanism appears durable across future rule cycles.